



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/895,141	06/29/2001	Seymour Benzer	30431.3US01	8276

26941 7590 08/07/2003

MANDEL & ADRIANO
55 SOUTH LAKE AVENUE
SUITE 710
PASADENA, CA 91101

[REDACTED] EXAMINER

SPIVACK, PHYLLIS G

[REDACTED] ART UNIT [REDACTED] PAPER NUMBER

1614

DATE MAILED: 08/07/2003

||

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/895,141	Applicant(s) Benzer et al.
	Examiner Phyllis G. Spivack	Art Unit 1614
-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --		
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>3</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.		
- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).		
Status		
1) <input checked="" type="checkbox"/> Responsive to communication(s) filed on <u>May 22, 2003</u> .		
2a) <input type="checkbox"/>	This action is FINAL .	2b) <input checked="" type="checkbox"/> This action is non-final.
3) <input type="checkbox"/> Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.		
Disposition of Claims		
4) <input checked="" type="checkbox"/> Claim(s) <u>1-22</u> is/are pending in the application.		
4a) Of the above, claim(s) <u>12-22</u> is/are withdrawn from consideration.		
5) <input type="checkbox"/> Claim(s) _____ is/are allowed.		
6) <input checked="" type="checkbox"/> Claim(s) <u>1-11</u> is/are rejected.		
7) <input type="checkbox"/> Claim(s) _____ is/are objected to.		
8) <input type="checkbox"/> Claims _____ are subject to restriction and/or election requirement.		
Application Papers		
9) <input type="checkbox"/> The specification is objected to by the Examiner.		
10) <input type="checkbox"/> The drawing(s) filed on _____ is/are a) <input type="checkbox"/> accepted or b) <input type="checkbox"/> objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
11) <input type="checkbox"/> The proposed drawing correction filed on _____ is: a) <input type="checkbox"/> approved b) <input type="checkbox"/> disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.		
12) <input type="checkbox"/> The oath or declaration is objected to by the Examiner.		
Priority under 35 U.S.C. §§ 119 and 120		
13) <input type="checkbox"/> Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) <input type="checkbox"/> All b) <input type="checkbox"/> Some* c) <input type="checkbox"/> None of: 1. <input type="checkbox"/> Certified copies of the priority documents have been received. 2. <input type="checkbox"/> Certified copies of the priority documents have been received in Application No. _____. 3. <input type="checkbox"/> Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).		
*See the attached detailed Office action for a list of the certified copies not received.		
14) <input checked="" type="checkbox"/> Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). a) <input type="checkbox"/> The translation of the foreign language provisional application has been received.		
15) <input type="checkbox"/> Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.		
Attachment(s)		
1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)		
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)		
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s). <u>3, 10</u>		
4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____		
5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)		
6) <input type="checkbox"/> Other: _____		

Art Unit: 1614

Applicants' Response to the Restriction Requirement filed May 22, 2003, Paper No. 9, is acknowledged. Applicants elected with traverse Group I, claims 1-11, which represent all of the claims presently under consideration.

No reasons for the traversal are advanced.

Claims 12-22 are withdrawn from consideration by the Examiner as being drawn to non-elected inventions, 37 C FR 1.142(b). Re-confirmation is requested when Applicants respond to this Office Action.

Two Information Disclosure Statements filed October 15, 2001 and February 12, 2002, respectively, Paper Nos. 3 and 10, are further acknowledged and have been reviewed.

Claims 1-7 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the administration of 4-phenylbutyric acid to Drosophila, does not reasonably provide enablement for any subject. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims. The claims are directed to extending the life span of any subject. The specification provides support for extending the life span of Drosophila comprising administering one particular inhibitor of histone deacetylase.

Attention is directed to In re Wands, 8 USPQ2d 1400 where the court set forth factors to consider when assessing whether or not a disclosure would require undue experimentation. These factors are:

- 1) the quantity of experimentation necessary

Art Unit: 1614

- 2) the amount of direction or guidance provided
- 3) the presence or absence of working examples
- 4) the nature of the invention
- 5) the state of the art
- 6) the relative skill of those in the art
- 7) the predictability of the art and
- 8) the breadth of the claims.

The instant specification fails to provide guidance that would allow the skilled artisan background sufficient to practice the instant invention without resorting to undue experimentation in view of further discussion below.

The nature of the invention, state of the prior art, relative skill of those in the art and the predictability of the art

The claimed invention relates to life span extension of any subject.

The relative skill of those in the art is generally that of a Ph.D or M.D.

Each particular "subject" has its own specific genetic characteristics. The broad recitation "extending the life span of a subject" is inclusive of many organisms that presently have no established successful therapies. In view of the specificity of the enzyme receptor for each particular inhibitor of histone deacetylase, a high degree of unpredictability would reasonably be expected.

Art Unit: 1614

It is clear the art to which the present invention relates is highly unpredictable and unreliable with respect to conclusions drawn from laboratory data extrapolated to clinical efficacy.

The breadth of the claims

The claims are very broad and inclusive of any subject.

The amount of direction or guidance provided and the presence or absence of working examples

The working examples are limited to Drosophila.

The quantity of experimentation necessary

Applicants have failed to provide guidance for subjects other than Drosophila and histone deacetylases other than 4-phenylbutyric acid. The skilled artisan would expect the interaction of a particular inhibitor of histone deacetylase to be very specific and highly unpredictable absent a clear understanding of the structural and biochemical basis for each agent. The instant specification sets forth no such understanding nor any criteria for extrapolating beyond the administration of 4-phenylbutyric acid to Drosophila. Absent reasonable *a priori* expectation of success for using a particular histone deacetylase inhibitor to extend the life span of subjects other than Drosophila, one skilled in the would have to test extensively many compounds to discover which particular histone deacetylase inhibitors exhibit efficacy in a particular subject. Since each prospective embodiment, as well as future embodiments as the art progresses, would have to be empirically tested, undue experimentation would be required to practice the invention as it is claimed in its current scope. The specification provides inadequate guidance to do otherwise.

Art Unit: 1614

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1 is rejected under 35 U.S.C. 102(a) as being anticipated by Imai et al., Nature.

Imai teaches the administration of the potent inhibitor of histone deacetylase, trichostatin A, to extend the life span of yeast. See column 1 on page 797.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-5 are rejected under 35 U.S.C. 102(b) as being anticipated by Nudelman et al., Journal of Medicinal Chemistry (abstract).

Nudelman teaches the administration of the histone deacetylase inhibitor glycerol tributyrate, a butyric acid derivative recited in claim 3, as an antitumor agent to extend the life span of the treated animal with a B16F0 melanoma primary cancer.

No claim is allowed.

Any inquiry concerning this communication should be directed to Phyllis Spivack at telephone number 703-308-4703.

Phyllis Spivack

August 6, 2003

**PHYLLIS SPIVACK
PRIMARY EXAMINER**